488 related articles for article (PubMed ID: 24057287)
1. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma.
Kerkhofs TM; Baudin E; Terzolo M; Allolio B; Chadarevian R; Mueller HH; Skogseid B; Leboulleux S; Mantero F; Haak HR; Fassnacht M
J Clin Endocrinol Metab; 2013 Dec; 98(12):4759-67. PubMed ID: 24057287
[TBL] [Abstract][Full Text] [Related]
2. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.
Terzolo M; Baudin AE; Ardito A; Kroiss M; Leboulleux S; Daffara F; Perotti P; Feelders RA; deVries JH; Zaggia B; De Francia S; Volante M; Haak HR; Allolio B; Al Ghuzlan A; Fassnacht M; Berruti A
Eur J Endocrinol; 2013 Sep; 169(3):263-70. PubMed ID: 23704714
[TBL] [Abstract][Full Text] [Related]
3. High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up.
Mauclère-Denost S; Leboulleux S; Borget I; Paci A; Young J; Al Ghuzlan A; Deandreis D; Drouard L; Tabarin A; Chanson P; Schlumberger M; Baudin E
Eur J Endocrinol; 2012 Feb; 166(2):261-8. PubMed ID: 22048971
[TBL] [Abstract][Full Text] [Related]
4. Short-term variation in plasma mitotane levels confirms the importance of trough level monitoring.
Kerkhofs TM; Derijks LJ; Ettaieb MH; Eekhoff EM; Neef C; Gelderblom H; den Hartigh J; Guchelaar HJ; Haak HR
Eur J Endocrinol; 2014 Dec; 171(6):677-83. PubMed ID: 25201518
[TBL] [Abstract][Full Text] [Related]
5. Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma.
Kerkhofs TM; Derijks LJ; Ettaieb H; den Hartigh J; Neef K; Gelderblom H; Guchelaar HJ; Haak HR
Ther Drug Monit; 2015 Feb; 37(1):58-65. PubMed ID: 24887633
[TBL] [Abstract][Full Text] [Related]
6. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
[TBL] [Abstract][Full Text] [Related]
7. High-Dose Mitotane-Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma.
Pape E; Feliu C; Yéléhé-Okouma M; Colling N; Djerada Z; Gambier N; Weryha G; Scala-Bertola J
Oncologist; 2018 Mar; 23(3):389-390. PubMed ID: 29192018
[No Abstract] [Full Text] [Related]
8. Practical treatment using mitotane for adrenocortical carcinoma.
Terzolo M; Zaggia B; Allasino B; De Francia S
Curr Opin Endocrinol Diabetes Obes; 2014 Jun; 21(3):159-65. PubMed ID: 24732405
[TBL] [Abstract][Full Text] [Related]
9. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer.
Terzolo M; Pia A; Berruti A; Osella G; Alì A; Carbone V; Testa E; Dogliotti L; Angeli A
J Clin Endocrinol Metab; 2000 Jun; 85(6):2234-8. PubMed ID: 10852456
[TBL] [Abstract][Full Text] [Related]
10. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.
Williamson SK; Lew D; Miller GJ; Balcerzak SP; Baker LH; Crawford ED
Cancer; 2000 Mar; 88(5):1159-65. PubMed ID: 10699907
[TBL] [Abstract][Full Text] [Related]
11. Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.
Zancanella P; Pianovski MA; Oliveira BH; Ferman S; Piovezan GC; Lichtvan LL; Voss SZ; Stinghen ST; Callefe LG; Parise GA; Santana MH; Figueiredo BC
J Pediatr Hematol Oncol; 2006 Aug; 28(8):513-24. PubMed ID: 16912591
[TBL] [Abstract][Full Text] [Related]
12. Mitotane treatment for adrenocortical carcinoma: an overview.
De Francia S; Ardito A; Daffara F; Zaggia B; Germano A; Berruti A; Di Carlo F
Minerva Endocrinol; 2012 Mar; 37(1):9-23. PubMed ID: 22382612
[TBL] [Abstract][Full Text] [Related]
13. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.
Lerario AM; Worden FP; Ramm CA; Hesseltine EA; Stadler WM; Else T; Shah MH; Agamah E; Rao K; Hammer GD
Horm Cancer; 2014 Aug; 5(4):232-9. PubMed ID: 24849545
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial.
Kroiss M; Quinkler M; Johanssen S; van Erp NP; Lankheet N; Pöllinger A; Laubner K; Strasburger CJ; Hahner S; Müller HH; Allolio B; Fassnacht M
J Clin Endocrinol Metab; 2012 Oct; 97(10):3495-503. PubMed ID: 22837187
[TBL] [Abstract][Full Text] [Related]
15. Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study.
Hermsen IG; Fassnacht M; Terzolo M; Houterman S; den Hartigh J; Leboulleux S; Daffara F; Berruti A; Chadarevian R; Schlumberger M; Allolio B; Haak HR; Baudin E
J Clin Endocrinol Metab; 2011 Jun; 96(6):1844-51. PubMed ID: 21470991
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
[TBL] [Abstract][Full Text] [Related]
17. Contribution of Therapeutic Monitoring in the Assessment of Toxic Adverse Effects of Mitotane: a Case Report.
Jebabli N; Gaïes E; Eljebari H; Charfi R; Lakhal M; Klouz A; Salouage I; Trabelsi S
Therapie; 2015; 70(6):545-6. PubMed ID: 26242497
[TBL] [Abstract][Full Text] [Related]
18. Enzyme autoinduction by mitotane supported by population pharmacokinetic modelling in a large cohort of adrenocortical carcinoma patients.
Arshad U; Taubert M; Kurlbaum M; Frechen S; Herterich S; Megerle F; Hamacher S; Fassnacht M; Fuhr U; Kroiss M
Eur J Endocrinol; 2018 Oct; 179(5):287-297. PubMed ID: 30087117
[TBL] [Abstract][Full Text] [Related]
19. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.
Doghman M; Lalli E
Mol Cell Endocrinol; 2013 Dec; 381(1-2):66-9. PubMed ID: 23906534
[TBL] [Abstract][Full Text] [Related]
20. [Mitotane in the treatment of adrenal carcinoma].
Sane T
Duodecim; 2010; 126(17):2040-6. PubMed ID: 21053521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
